Latest Ibritumomab tiuxetan Stories
NEW YORK, Nov.
SEATTLE, Oct. 22 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr.
SEATTLE, Sept. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
SEATTLE, June 22 /PRNewswire-FirstCall/ -- Updated follow-up phase III EXTEND (PIX 301) clinical trial data enhances previously reported superior response rates for pixantrone over comparator including in high risk patient subgroups Additional Clinical Studies Also Highlighted at Pan Pacific Conference Randomized phase III; PIX 302-Pixantrone plus rituximab significantly improves CR rate (35% vs.
- Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma - Phase III study underway to explore potential of Afinitor to prevent relapse in patients with the most common type of non-Hodgkin's lymphoma EAST HANOVER, N.J., June 8 /PRNewswire/ -- New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1).
Pixantrone Named-Patient Program Initiated in Europe SEATTLE, May 7 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) reported recent accomplishments and financial results for the quarter ended March 31, 2009.
SEATTLE, April 6 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it received $6.5 million from Spectrum Pharmaceuticals, Inc.
Company estimates sales of pixantrone, if approved, could potentially reach $1 billion by 2014 SEATTLE, March 19 /PRNewswire-FirstCall/ -- Craig Philips, President of Cell Therapeutics, Inc.
Net operating expenses decreased by 33% in 2008; Forecast cutting net operating expenses by approximately 50% in 2009 CTI expects to complete pixantrone NDA submission in Q2 2009 SEATTLE, March 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
CTI to focus on Pixantrone and OPAXIO Approval and Commercialization SEATTLE, Feb. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.
- The word or words serving to define another word or expression, as in a dictionary entry.